Bicara Therapeutics (BCAX) said Monday it closed its initial public offering of more than 20.1 million shares at $18 apiece, with gross proceeds of about $362 million.
The company said the offering includes almost 2.63 million shares issued upon the exercise in full by the underwriters of their option to purchase additional shares. The company sold all the shares in the IPO.
Bicara's shares began trading on the Nasdaq Global Market on Friday under the "BCAX" ticker.
Shares of the company closed 8.5% higher on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.